Triazolam: monitored release in the United Kingdom

Area of Science:

• Pharmacology
• Clinical Medicine
• Psychiatry

Background:

• Triazolam is a benzodiazepine hypnotic used for insomnia.
• Understanding its real-world use and patient outcomes is crucial for clinical practice.

Purpose of the Study:

• To assess the safety and efficacy of triazolam in a large patient population.
• To analyze dosage patterns and identify factors influencing triazolam use.

Main Methods:

• A monitored release study involving 3,010 patients in the United Kingdom.
• Data collection on patient demographics, prescribed triazolam dosage, sleep quality, and adverse events.

Main Results:

• The majority of patients (71.3%) received a 0.25 mg dose of triazolam.
• 84.7% of patients reported adequate sleep, with an overall side effect incidence of 12.2%.
• Dosage varied by age, with older patients (over 60) more frequently receiving lower doses (0.125 mg or 0.25 mg).

Conclusions:

• Triazolam demonstrated efficacy in improving sleep for the majority of patients in a real-world setting.
• The incidence of side effects was relatively low, suggesting a favorable safety profile.
• Age appears to be a factor in triazolam dosage selection, with older individuals receiving lower doses.